# A Study of IMC-A12 Every 2 Weeks in Patients With Tumors Who No Longer Respond to Treatment or No Treatment is Available

> **NCT00785941** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 16 (actual)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **BIOLOGICAL:** IMC-A12
- **BIOLOGICAL:** IMC-A12
- **BIOLOGICAL:** IMC-A12
- **BIOLOGICAL:** IMC-A12
- **BIOLOGICAL:** IMC-A12

## Key facts

- **NCT ID:** NCT00785941
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-04
- **Primary completion:** 2007-10
- **Final completion:** 2007-11
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2011-10-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00785941

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00785941, "A Study of IMC-A12 Every 2 Weeks in Patients With Tumors Who No Longer Respond to Treatment or No Treatment is Available". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00785941. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*